ValuEngine upgraded shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) from a hold rating to a buy rating in a research report sent to investors on Thursday morning.
Separately, Piper Jaffray Companies reissued an overweight rating and issued a $6.00 target price on shares of Aptevo Therapeutics in a report on Thursday, October 5th.
Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.08. Aptevo Therapeutics had a negative net margin of 296.64% and a negative return on equity of 64.80%. The firm had revenue of $10.76 million for the quarter.
WARNING: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2958243/aptevo-therapeutics-inc-apvo-upgraded-by-valuengine-to-buy.html.
A number of hedge funds and other institutional investors have recently modified their holdings of APVO. Dimensional Fund Advisors LP raised its holdings in shares of Aptevo Therapeutics by 8.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock valued at $2,187,000 after buying an additional 78,109 shares during the last quarter. Precept Management LLC bought a new stake in shares of Aptevo Therapeutics during the second quarter valued at approximately $1,210,000. Legal & General Group Plc raised its holdings in shares of Aptevo Therapeutics by 11,751.3% during the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock valued at $815,000 after buying an additional 390,379 shares during the last quarter. Finally, Spark Investment Management LLC raised its holdings in shares of Aptevo Therapeutics by 167.4% during the second quarter. Spark Investment Management LLC now owns 61,500 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 38,500 shares during the last quarter. 39.16% of the stock is currently owned by hedge funds and other institutional investors.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.